# Surginex Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surginex-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.surginex.com
- Total disclosed funding: $3.4M
- Latest round: Series A (Nov 1, 2021)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2020, Surginex Co., Ltd., a.k.a. Surginex is a biotechnology company that develops drug delivery technology efficiency to the body by using nanoparticles such as exosomes and liposomes. The company is developing and upgrading Odysseus, an in-silico platform that combines a drug delivery system and a three-dimensional structure between cells by applying AI-based molecular dynamics technology. In March 2024, Surginex raised KRW 8.5 billion in venture funding from Kiwoom Investment, Partners Investment, Hana Ventures, POSCO Capital, LSK Investment, and Laguna Investment. As of July 2024, Sejun Kim is the CEO of the company.

Surgenex offers a range of scientific services, including the development and provision of investigational kits, custom exosomes, and genetic testing services. The company’s products feature tools for RNA and protein expression analysis, and they provide custom CRISPR/Cas9 design and RNA synthesis. Additionally, the firm conducts physical and chemical analyses of materials and offers histopathology services.

The company plans to use its proceeds from March 2024 funding to establish a mass production process for its lipid nanoparticles and achieve a global license for commercialization.

## Funding rounds

- Series A, Nov 1, 2021, $3.4M — KNet Investment Partners, Laguna Investment

## Investors

- KNet Investment Partners (https://capitalatlas.ai/funds/knet-investment-partners) — Series A
- Laguna Investment (https://capitalatlas.ai/funds/laguna-investment) — Series A